Tumour therapy using Salmonella

Bibliography

• NAUTS HC, SWIFT WE, COLEY BL: The treatment of malignant tumours by bacterial toxins as developed by the late William B. Coley MD, reviewed in the light of modern research. Cancer Res. (1946) 6: 205–216.
   Google Scholar
• GILL GV, HOLDEN A: A malignant pleural effusion infected with Salmonella enteritidis. Thorax (1996) 51:104–105.
   PubMed Web of Science ®Google Scholar
• GIEL CP: Abscess formation in a pheochromocytoma. N. Engl. J. Med. (1954) 251: 980–982.
   Google Scholar
• GRAHAM FO, COLEMAN PN: Infection of a secondary carcinoma bySalmonellamontevideo. Br. Med.J. (1952) 1: 1116.
   PubMed Web of Science ®Google Scholar
• WOLFE MS, LOURIA DB, ARMSTRONG D, BLEVINS A:Saknonellosis in patients with neoplastic disease. A review of 100 episodes at Memorial Cancer Center over a 13-year period. Arch. Intern. Med. (1971) 128:546–554.
   PubMed Web of Science ®Google Scholar
• COLEY WB: The cancer symposium at Lake Mohonk.Am. J. Surg. (1926) 1:22–23.
   Google Scholar
• CARSWELL EA, OLD 41, KASSEL RL, GREEN S, FIORE N,WILLIAMSON B: An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. USA (1975) 72:3666–3670.
   PubMed Web of Science ®Google Scholar
• FLAD H-D, LOPPNOW H, RIETSCHEL ET, ULMER AJ:Agonists and antagonists for lipopolysaccharide-induced cytokines. Immunobiology. (1993) 187:303–316.
   PubMed Web of Science ®Google Scholar
• VAUPEL P, SCHLENGER K, KNOOP C, HOCKEL M:Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computer-ized 02 tension measurements. Cancer Res. (1991) 51: 3316–3322.
   Google Scholar
• PARKER RC, PLUMMBER HC, SIEBENMANN CO, CHAPMAN MG: Effect of histolyticus infection and toxin on transplantable mouse tumors. Proc. Soc. Exp. Biol. Med. (1947) 66:461–465.
   PubMed Web of Science ®Google Scholar
• ENGELBART K, GERICKE D: Oncolysis by Clostridia. V.Transplanted tumors of the hamster. Cancer Res. (1964) 24:239–243.
   PubMed Web of Science ®Google Scholar
• THIELE EH, ARISON RN, BOXER GE: Oncolysis by Clostridia. IV. Effect of nonpathogenic Clostridial spores in normal and pathological tissues. Cancer Res. (1963) 24:234–238.
   Web of Science ®Google Scholar
• MOSE JR, MOSE G: Oncolysis by Clostridia . I. Activity of Clostridium butyricum (M-55) and other nonpatho-genic Clostridia against the Ehrlich Carcinoma. Cancer Res. (1964) 24:212–216.
   PubMed Web of Science ®Google Scholar
• CAREY RW, HOLLAND JF, WHANG HY, NETER E, BRYANT B: Clostridial oncolysis in man. Eur. J. Cancer (1967) 3:37–46.
   Google Scholar
• FOX ME, LEMMON MJ, MAUCHLINE ML, et al.: Anaerobic bacteria as a delivery system for cancer gene therapy: in vitro activation of 5-fluorocytosine by genetically engineered Clostridia. Gene Ther. (1996) 3:173–178.
   Google Scholar
• LEMMON MJ, ELWELL JH, BREHM JK, et al.: Anaerobic bacteria as a gene delivery system to tumors. Proc. Am. Assoc. Cancer Res. (1994) 35:374.
   Google Scholar
• LEMMON MJ, VAN ZIJL P, FOX ME, et al.: Anaerobicbacteria as a gene delivery system that is controlled by the tumor microenvironment. Gene Ther. (1997) 4:791–796.
   PubMed Web of Science ®Google Scholar
• MINTON NP, MAUCHLINE ML, LEMMON MJ, et al.: Chemotherapeutica tumour targeting using clostridial spores. FEMS Micro biol. Rev. (1995) 17:357–364.
   PubMed Web of Science ®Google Scholar
• JACKSON AM, IVSHINA AV, SENKO 0 et al.: Prognosis of intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer by immunological urinary measurement: statistically weighted syndrome analysis. J. Urol. (1998) 159: 1054–1063.
   Google Scholar
• JIMENEZ-CRUZ JF, VERA-DONOSO CD, LEIVA 0 et al.: Intravesicalirnmunoprophylaxis in recurrent superfi-cial bladder cancer (Stage Ti): multicenter trial comparing bacille Calmette-Guérin and interferon-alpha. Urology (1997) 50:529–535.
   PubMed Web of Science ®Google Scholar
• FRIBERG S: BCG in the treatment of superficial cancer of the bladder: a review. Med. Oncol. Tumour.Pharmaco-ther. (1993) 10:31–36.
   PubMed Web of Science ®Google Scholar
• STEG A, SICARD D, LELEU C, DEBRE B, BOCCON-GIBOD L: Systemic complications of intravesical BCG therapy for bla (kr cancer. Lancet (1985) 2(8460):899.
   PubMedGoogle Scholar
• MCPARLAND C, COTTON DJ, GOWDA KS, HOEPPNER VH,MARTIN WT, WECKWORTH PF: Miliary Mycobacterium bovis induced by intravesical bacille Calmette-Guérin immunotherapy. Am. Rev. Respir. Dis. (1992) 146: 1330–1333.
   Google Scholar
• TRUELSON T, WISHNOW KI, JOHNSON DE: Epididymo-orchitis developing as a late manifestation of intravesical bacillus Calmette-Guérin therapy and masquerading as a primary testicular malignancy: a report of 2 cases. J. Urol. (1992) 148: 1534–1535.
   Google Scholar
• TSE V, KHADRA M, EISINGER D, MITTERDORFER A, BOULAS J, ROGERS J: Nephrogenic adenoma of the bladder in renal transplant and non-renal transplant patients: a review of 22 cases. Urology (1997) 50:690–696.
   PubMed Web of Science ®Google Scholar
• HURLE R, LOSA A, RANIERI A, LEMBO A: Acid-fast bacilli persisting in the genitourinary tract 3 years after intravesical bacille Calmette-Guérin therapy for bladder carcinoma. Br. J. Urol. (1998) 81:496–497.
   PubMedGoogle Scholar
• HALPERN BN, BIOZZI G, STIFFEL C, MOUTON D: Inhibi-tion of tumour growth by administration of killed Corynebacterium parvum. Nature (1966) 212:853–854.
   Google Scholar
• BALCH CM, SMALLEY RV, BARTOLUCCI AA, BURNS D, PRESANT CA, DURANT JR: A randomized prospective clinical trial of adjuvant C. parvum immunotherapy in 260 patients with clinically localized melanoma (Stage I): prognostic factors analysis and preliminary results of immunotherapy. Cancer (1982) 49:1079–1084.
   PubMed Web of Science ®Google Scholar
• FISHER B, BROWN A, WOLMARK N, et al.: Evaluation ofthe worth of Corynebacterium parvum in conjunction with chemotherapy as adjuvant treatment for primary breast cancer. Eight-year results from the National Surgical Adjuvant Breast and Bowel Project B-10. Cancer (1990) 66:220–227.
   PubMed Web of Science ®Google Scholar
• CHATFIELD SN, CHARLES IG, MAKOFF AJ, et al.: Use of thenirB promoter to direct the stable expression of heterologous antigens in Salmonella oral vaccine strains: development of a single-dose oral tetanus vaccine. Biotechnology (1992) 10:888–892.
   PubMed Web of Science ®Google Scholar
• CHATFIELD SN, STRAHAN K, PICKARD D, CHARLES IG,HORMAECHE CE, DOUGAN G: Evaluation of Salmonella typbimurium strains harbouring defined mutations in htrA and aroA in the murine saknonellosis model. Microb Pathol. (1992) 12: 145–151.
   Web of Science ®Google Scholar
• LEVIN MM, HERRINGTON D, MURPHY JR, et al.: Safety,infectivity, irnmumogenicity and in vivo stability of two attenuated auxotrophic mutant strains of Salmonella typbi. J. Clin. Invest. (1987) 79:888–902.
   Google Scholar
• GONZALES C, HONE D, NORIEGA FR, et al.: Salmonella typbi vaccine strain CVD904 expressing the circum-sporozoite protein of Plasmodium falciparum: strain construction and safety and immunogenicity in humans. J. Infect. Dis. (1994) 169: 927–931.
   PubMed Web of Science ®Google Scholar
• HARDT WD, URLAUB H, GALAN JE: A substrate of the centisome 63 Type BI protein secretion system of Salmonella typbimurium is encoded by a cryptic bacteriophage. Proc. Natl. Acad. Sci. USA (1998) 95:2574–2579.
   PubMed Web of Science ®Google Scholar
• HOHMANN EL, OLETTA CA, MILLER SI: Evaluation of aphoP/phoQ-deleted, aroA-deleted live oral Salmonella typbi vaccine strain in human volunteers. Vaccine (1996) 14:19–24.
   PubMed Web of Science ®Google Scholar
• O'CALLAGHAN D, MASKELL D, LIEW FY, EASMON CF, DOUGAN G: Characterization of aromatic- and purine-dependent Salmonella typbimurium: attenua-tion, persistence and ability to induce protective immunity in Balb/c mice. Infect. Immun. (1988) 56: 419–423.
   Google Scholar
• TACKET CO, HONE DM, CURTISS III R, et al.: Comparisonof the safety and irnmunogenicity of delta aroC delta aroD and delta cya delta crp Salmonella typbi strains in adult volunteers. Infect. Immun. (1992)60:536-641.
   Google Scholar
• CHABALGOITY JA, KHAN CMA, NASH AA, HORMAECHECE: A Salmonella typbimurium htrA live vaccine expressing multiple copies of a peptide comprising amino acids 8-23 of herpes simplex virus glycoprotein D as a genetic fusion to tetanus toxin fragment C protects mice from herpes simplex virus infection. Mol. Micro biol. (1996) 19:791–801.
   PubMed Web of Science ®Google Scholar
• HOISETH SKJ, STOCKER BAD: Aromatic-dependent Salmonella typbimurium are non-virulent and effective as live vaccines. Nature (1981) 291: 238–239.
   Google Scholar
• CURTISS III R, KELLY SM, GULIG PA, NAKAYAMA K: Selective delivery of antigens by recombinant bacteria. Curr. Top. Micro biol. Immunol. (1989)146:35-49.
   Google Scholar
• GALAN J, CURTISS III R: Virulence and vaccine potentialof phoP mutants of S. typbimurium. Microb. Pathog. (1989) 6:422–443.
   Google Scholar
• MILLER SI: PhoP/PhoQ: macrophage-specific modula-tors of Salmonella virulence Mol. Microbiol. (1991) 5:2073–2078.
   Google Scholar
• DORMAN CJ, CHATFIELD S, HIGGINS CF, HAYWARD C,DOUGAN G: Characterization of porin and ompR mutants of a virulent strain of Salmonella typbimurium: ompR mutants are attenuated in vivo. Infect. Immun. (1989) 57:2136–2140.
   Google Scholar
• KELLY SM, BOSECKER BA, CURTISS III R: Characteriza-tion and protective properties of attenuated mutants of Salmonella cboleraesuis. Infect. Immun. (1992) 60:4881–4890.
   PubMed Web of Science ®Google Scholar
• PAWELEK JM, LOW KB, BERMUDES D: Tumor-targetedSalmonella as a novel anticancer vector. Cancer Res. (1997) 57:4537–4544.
   PubMed Web of Science ®Google Scholar
• EISENSTEIN TK, BUSHNELL B, MEISSLER JJ, JR., DALAL N,SCHAFER R, HAVAS HF: Immunotherapy of a plasmacy-toma with attenuated Salmonella. Med. Oncol. (1995) 12:103–108.
   PubMed Web of Science ®Google Scholar
• SOMERVILLE JE, CASSAIANO L, JR., BAINBRIDGE B,CUNNINGHAM MD, DARVEAU RP: A novel Escbericbia coli lipid A mutant that produces and antiinflarnma-tory lipopolysaccharide. J. Clin. Invest. (1996) 97:359–365.
   PubMed Web of Science ®Google Scholar
• KOVACH NL, YEE E, MUNFORD RS, RAETZ CRH, HARLANJM: Lipid IVA inhibits synthesis and release of tumor necrosis factor induced by lipopolysaccharide in human whole blood ex vivo. J. Exp. Med. (1990) 172:77–84.
   PubMed Web of Science ®Google Scholar
• RICK PD, OSBORN MJ: Lipid A mutants of Salmonellatypbimurium: characterization of a conditional lethal mutant in 3-deoxy-d-mannooctulosonate-8-phosphate synthetase. J. Biol. Chem. (1 9 7 7) 252:4895-4903.
   Google Scholar
• SOMERVILLE JE, CASSIANO L, Jr., DARVEAU RP: Escberi-cbia coli msbB gene as a virulence factor and a therapeutic target. Infect. Immun. (1999) 67:6583–6590.
   PubMed Web of Science ®Google Scholar
• LOW KB, ITTENSOHN M, LE T, et al.: Lipid A mutantSalmonella with suppressed virulence and TNF-a induction retain tumor-targeting in vivo. Nature Biotech. (1999) 17: 37–41.
   Google Scholar
• CLAIRMONT CD, BERMUDES KB, LOW J, et al.: VNP20009,a genetically modified Salmonella typbimurium: anti-tumor efficacy, toxicology and biodistribution in preclinical models. Clin. Cancer Res. (1999) 5:3830s.
   Google Scholar
• KHAN SA, EVEREST P, SERVOS S, et al.: A lethal role forlipid A in Salmonella infections. Mol. Mircobiol. (1998) 29:571–579.
   PubMed Web of Science ®Google Scholar
• LUO X, ITTENSOHN M, LOW B, et al.: Geneticallymodified Salmonella typbimurium inhibited growth of primary tumors and metastases. Proc. Am. Assoc. Cancer Res. (1999) 40:476.
   Google Scholar
• ZHENG LM, LUO X, FISCHER J, et al.: Attenuated Salmonella typhimurium inhibited tumor metastasis in vivo. Proc. Am. Assoc. Cancer Res. (1997) 38: 9.
   Google Scholar
• LOW KB, ITTENSOHN M, LIN S, et al.: VNP20009, a geneti-cally modified Salmonella typhimurium for treatment of solid tumors. Proc. Am. Assoc. Cancer Res. (1999)40:87.
   Google Scholar
• KOPS SK, LUO X, FISCHER J, et al.: Salmonella typhimurium as an anti-cancer vector: localization within solid tumors. Proc. Am. Assoc. Cancer Res. (1997) 38:7.
   Google Scholar
• JAIN RK: Barriers to drug delivery in solid tumors. Sci. Am. (1994) 271: 58–65.
   Google Scholar
• JAIN RK: Haemodynarnic and transport barriers to the treatment of solid tumours. Int. J. Radiat. Biol. (1991) 60: 85–100.
   Google Scholar
• CHEN JJ, SUN Y, NABEL GJ: Regulation of the pro-inflammatory effects of Fas ligand (CD95L). Science (1998) 282: 1714–1717.
   Google Scholar
• SALTZMAN DA, HEISE CP, HASZ DE, et al.: Attenuated Salmonella typhimurium containing interleukin-2 decreases MC-38 hepatic metastases: a novel anti-tumor agent. Cancer Biother. Radiopharm. (1996) 11: 145–153.
   Google Scholar
• SALTZMAN DA, KATSANIS E, HEISE CP, et al.: Patterns of hepatic and splenic colonization by an attenuated strain of Salmonella typhimurium containing the gene for human interleukin-2: A novel tumor agent. Cancer Biother. Radiopharm. (1997) 12:37–43.
   PubMed Web of Science ®Google Scholar
• CARRIER MJ, CHATFIELD SN, DOUGAN G, et al.: Expres-sion of human IL-113 in Salmonella typbimurium. A model system for the delivery of recombinant therapeutic proteins in vivo. J. Immunol. (1992) 148:1176–1181.
   Google Scholar
• SLOBBE L, LOCKHART E, O'DONNELL MA, MACKINTOSH C, DE LISLE G, BUCHAN G: An in vivo comparison of bacillus Calmette-Guérin (BCG) and cytokine-secreting BCG vaccines. Immunol. (1999)96:517-523.
   Google Scholar
• KING I, FENG M, LUO X, LIN S, BERMUDES D, ZHENG L-M: Tumor-targeted Salmonella expressing cytosine deaminase gene converted 5-fluorocytosine to 5-fluorouracil and inhibited tumor growth in vivo. Proc. Am. Assoc. Cancer Res. (1998) 39:512.
   Google Scholar
• ZHENG L-M, LUO X, LI Z, et al.: Tumor-selective Salmonella as a gene delivery vector for cancer gene therapy. J. Immunother. (1999) 22:461.
   Google Scholar
• LIN SL, SPINKA TL, LE TX, et al.: Tumor-directed delivery and amplification of tumor-necrosis factor-a (TNF) by attenuated Salmonella typbimuirum. Clinical Cancer Res. (1999) 5:3822s.
   Google Scholar
• BELCOURT MF, PENKETH PG, HODNICK WF, et al.: Expression of the mitomycin C activating enzyme DT-diaphorase in tumor-targeted Salmonella. Proc. Am. Assoc. Cancer Res. (2000) 41: 466.
   Google Scholar
• LEE K, ZHENG L-M, LUO X, et al.: Comparative toxico-logical evaluation in monkeys, pigs and mice, of a genetically-engineered Salmonella (VNP20009) being developed as an anti-tumor agent. Intl. J. Toxicol. (2000) 19:19–25.
   Web of Science ®Google Scholar